Judge Rules TKT Infringes Amgen Erythropoietin Patents

Law360, New York (October 16, 2004, 12:00 AM EDT) -- A federal judge has ruled in biotech company Amgen Inc.’s favor in its seven-year legal battle against Transkaryotic Therapies Inc. (TKT) and Aventis Pharmaceuticals Inc. over patents for an anemia treatment.

In a 290-page ruling, Judge William G. Young of U.S. District Court for the District of Massachusetts upheld four of Amgen's patent claims and said two of them had been infringed by TKT.

The patents cover the production of erythropoietin, a natural hormone produced by the kidneys that stimulates the production of red blood cells....
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.